ArticleThrombosis journal2017
Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis.
Article in Thrombosis journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- The American Venous Forum clinical practice guideline on the care of patients with upper extremity deep venous thrombosis.Journal of vascular surgery. Venous and lymphatic disorders · 2026Guideline
- A systematic review and meta-analysis of the incidence of post-thrombotic syndrome, recurrent thromboembolism, and bleeding after upper extremity vein thrombosis.Journal of vascular surgery. Venous and lymphatic disorders · 2024Pooled it
- Review
- Direct Oral Anticoagulants for the Treatment of Unusual-Site Venous Thrombosis: An Update.Pharmaceutics · 2025Review
- Unveiling the complexities of catheter-related thrombosis: risk factors, preventive strategies, and management.Journal of thrombosis and thrombolysis · 2025Review
- Article
- Treatment of pacemaker-induced superior vena cava syndrome by direct oral anticoagulant.Thrombosis journal · 2023Article
- A Single Center Retrospective Cohort Study Comparing Different Anticoagulants for the Treatment of Catheter-Related Thrombosis of the Upper Extremities in Women With Gynecologic and Breast Cancer.Frontiers in cardiovascular medicine · 2022Article
- Superior vena cava syndrome after pacemaker implantation treated with direct oral anticoagulation.Thrombosis journal · 2021Article
- Direct oral anticoagulants for unusual-site venous thromboembolism.Research and practice in thrombosis and haemostasis · 2021Article
- Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience.Journal of thrombosis and thrombolysis · 2020Article
- Diagnostic and Therapeutic Management of Upper Extremity Deep Vein Thrombosis.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpper extremity deep vein thrombosis (UEDVT) constitutes around 10% of all DVT, and can cause both pulmonary embolism (PE) and postthrombotic syndrome (PTS) in the arm. The incidence of secondary UEDVT is increasing due to widespread use of central venous catheters in patients with cancer and other chronic diseases. The safety and efficacy of using new direct acting oral anti coagulants (DOAC) in the treatment of UEDVT has not been systematically evaluated. Our aims were to evaulate efficacy, safety, and risk of recurrence of venous thromboembolism (VTE) during DOAC treatment in UEDVT patients.
methodsData from the Swedish national anticoagulation registry (AuriculA) was retrospectively evaluated for all 55 patients (27 men aged 23-86 years, and 28 women aged 18-75 years) treated with DOAC because of UEDVT between 2012 and 2015 in the southernmost hospital region of Sweden with 1.3 million inhabitants in 2016. Patients were followed for 6 months.
resultsDuring 6 months after institution of DOAC treatment there was one recurrence (2%) of DVT during treatment and two (4%) recurrences after cessation of treatment. No patient died, whereas one (2%) suffered a clinically relevant nonmajor bleeding.
conclusionDOAC can be used in the treatment of UEDVT patients with acceptable efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.